Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

Guizhou Bailing Group Pharmaceutical Co., Ltd. (002424.SZ)

Compare
4.0000
-0.0100
(-0.25%)
At close: April 18 at 3:04:36 PM GMT+8
Loading Chart for 002424.SZ
  • Previous Close 4.0100
  • Open 4.0000
  • Bid 4.0000 x --
  • Ask 4.0100 x --
  • Day's Range 3.9500 - 4.0100
  • 52 Week Range 2.9800 - 6.7100
  • Volume 12,681,200
  • Avg. Volume 23,223,118
  • Market Cap (intraday) 5.59B
  • Beta (5Y Monthly) 0.47
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3400
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date May 29, 2020
  • 1y Target Est --

Guizhou Bailing Group Pharmaceutical Co., Ltd. research, develops, produces, and sells medicines in China. The company provides medicines in the form of tablets, capsules, granules, syrups, powders, pills, tinctures, sprays, lotions, and cream for cardiovascular and cerebrovascular diseases, cough, cold, pediatric, and gynecologic diseases. Guizhou Bailing Group Pharmaceutical Co., Ltd. was founded in 1999 and is headquartered in Anshun, China.

www.gzbl.com

6,582

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 002424.SZ

View More

Performance Overview: 002424.SZ

Trailing total returns as of 4/18/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

002424.SZ
3.90%
SSE Composite Index (000001.SS)
2.24%

1-Year Return

002424.SZ
39.67%
SSE Composite Index (000001.SS)
6.59%

3-Year Return

002424.SZ
44.52%
SSE Composite Index (000001.SS)
2.54%

5-Year Return

002424.SZ
52.78%
SSE Composite Index (000001.SS)
15.44%

Compare To: 002424.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 002424.SZ

View More

Valuation Measures

Annual
As of 4/18/2025
  • Market Cap

    5.59B

  • Enterprise Value

    7.25B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.35

  • Price/Book (mrq)

    1.61

  • Enterprise Value/Revenue

    1.72

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -11.04%

  • Return on Assets (ttm)

    -4.01%

  • Return on Equity (ttm)

    -12.36%

  • Revenue (ttm)

    4.23B

  • Net Income Avi to Common (ttm)

    -466.78M

  • Diluted EPS (ttm)

    -0.3400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    170.62M

  • Total Debt/Equity (mrq)

    52.50%

  • Levered Free Cash Flow (ttm)

    228.45M

Research Analysis: 002424.SZ

View More

Company Insights: 002424.SZ

Research Reports: 002424.SZ

View More

People Also Watch